Illumina Reports Q3 2026 Growth Driven by NovaSeq X Adoption and Clinical Demand
Illumina (ILMN) reported strong third-quarter results for 2026, characterized by a non-GAAP revenue of $1.17 billion and an adjusted diluted EPS of $1.44, representing a 7% year-over-year increase. Growth was primarily fueled by high demand in clinical sequencing and the successful transition to the NovaSeq X platform, which now accounts for 84% of total high throughput volume. The company demonstrated significant operational efficiency, with an adjusted non-GAAP operating margin of 25.0%, exceeding previous guidance. While research and applied consumables saw a slight decline, management noted signs of stabilization in that segment. Following these results, Illumina raised its full-year revenue, EPS, and operating margin guidance, signaling confidence in continued consumable sales momentum through the fourth quarter.
Tickers: $ILMN
Topics: EPS NovaSeq X Placements Operating Margin Revenue Growth Sequencing Consumables